Loading
Cabaletta Bio, Inc. is a biotechnology firm in the clinical development stage, specializing in the invention and advancement of sophisticated engineered T cell therapies. Its core mission is to treat autoimmune diseases where B cells are implicated in producing harmful autoantibodies. The company's unique chimeric autoantibody receptor (CAAR) T cell platform is engineered to precisely target and eradicate these specific disease-causing B cells. Leading its pipeline is DSG3-CAART, which is currently in Phase I clinical trials. This candidate is being assessed for efficacy in two distinct conditions: mucosal pemphigus vulgaris, an autoimmune blistering skin disorder, and Hemophilia A in patients exhibiting Factor VIII alloantibodies. Cabaletta's broader product candidate portfolio also includes MuSK-CAART, a preclinical asset aimed at a particular subset of myasthenia gravis patients; FVIII-CAART, in the discovery phase for another subgroup of Hemophilia A sufferers; and DSG3/1-CAART, also a discovery-stage program, designed for mucocutaneous pemphigus vulgaris. The company maintains strategic alliances, including a collaboration with the University of Pennsylvania and a research pact with The Regents of the University of California. Founded in 2017 as Tycho Therapeutics, Inc., it adopted the name Cabaletta Bio, Inc. in August 2018 and is based in Philadelphia, Pennsylvania.
Regular session
$1.925
−$0.045 · -2.28%
Regular session · ET · Market data may be delayed.
Cabaletta Bio, Inc. is a biotechnology firm in the clinical development stage, specializing in the invention and advancement of sophisticated engineered T cell therapies. Its core mission is to treat autoimmune diseases where B cells are implicated in producing harmful autoantibodies. The company's unique chimeric autoantibody receptor (CAAR) T cell platform is engineered to precisely target and eradicate these specific disease-causing B cells. Leading its pipeline is DSG3-CAART, which is currently in Phase I clinical trials. This candidate is being assessed for efficacy in two distinct conditions: mucosal pemphigus vulgaris, an autoimmune blistering skin disorder, and Hemophilia A in patients exhibiting Factor VIII alloantibodies. Cabaletta's broader product candidate portfolio also includes MuSK-CAART, a preclinical asset aimed at a particular subset of myasthenia gravis patients; FVIII-CAART, in the discovery phase for another subgroup of Hemophilia A sufferers; and DSG3/1-CAART, also a discovery-stage program, designed for mucocutaneous pemphigus vulgaris. The company maintains strategic alliances, including a collaboration with the University of Pennsylvania and a research pact with The Regents of the University of California. Founded in 2017 as Tycho Therapeutics, Inc., it adopted the name Cabaletta Bio, Inc. in August 2018 and is based in Philadelphia, Pennsylvania.
Day range
Current $1.925
52-week range
Current $1.925
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
28
Expensive
Sentiment
43
Mixed
Risk
75
High Risk
Momentum
50
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Cabaletta Bio, Inc. is a biotechnology firm in the clinical development stage, specializing in the invention and advancement of sophisticated engineered T cell therapies. Its core mission is to treat autoimmune diseases where B cells are implicated in producing harmful autoantibodies. The company's unique chimeric autoantibody receptor (CAAR) T cell platform is engineered to precisely target and eradicate these specific disease-causing B cells. Leading its pipeline is DSG3-CAART, which is currently in Phase I clinical trials. This candidate is being assessed for efficacy in two distinct conditions: mucosal pemphigus vulgaris, an autoimmune blistering skin disorder, and Hemophilia A in patients exhibiting Factor VIII alloantibodies. Cabaletta's broader product candidate portfolio also includes MuSK-CAART, a preclinical asset aimed at a particular subset of myasthenia gravis patients; FVIII-CAART, in the discovery phase for another subgroup of Hemophilia A sufferers; and DSG3/1-CAART, also a discovery-stage program, designed for mucocutaneous pemphigus vulgaris. The company maintains strategic alliances, including a collaboration with the University of Pennsylvania and a research pact with The Regents of the University of California. Founded in 2017 as Tycho Therapeutics, Inc., it adopted the name Cabaletta Bio, Inc. in August 2018 and is based in Philadelphia, Pennsylvania.
Day range
Current $1.925
52-week range
Current $1.925
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Research and development | 142.67M USD | 97.2M USD | 55.42M USD | 39.3M USD | 32.49M USD |
| Selling, general, and administrative | 29.57M USD | 27.94M USD | 19.24M USD | 14.84M USD | 13.82M USD |
| Operating expenses | 172.24M USD | 125.14M USD | 74.66M USD | 54.14M USD | 46.31M USD |
| Interest income | 6.03M USD | 10.03M USD | 6.99M USD | 1.16M USD | 24K USD |
| Interest expense | 2M USD | 748K USD | — | — | — |
| Depreciation and amortization | 1.65M USD | 1.71M USD | 1.43M USD | 1.18M USD | 733K USD |
| Operating income | −172.24M USD | −125.14M USD | −74.66M USD | −54.14M USD | −46.31M USD |
| Net income | −167.86M USD | −115.86M USD | −67.68M USD | −52.98M USD | −46.29M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$16.33
748.31% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI16.22M0.00%2.3T USD0.03%$379.75-0.34%
State Street SPDR S&P Biotech ETFXBI10.46M0.10%10.08B USD0.35%$146.67-2.37%
iShares Russell 2000 ETFIWM8.43M0.01%78.56B USD0.19%$275.02-0.97%
Vanguard Extended Market ETFVXF5.91M0.01%95.4B USD0.05%$231.6-0.81%
Fidelity Enhanced Small Cap ETFFESM3.55M0.05%6.41B USD0.28%$44.795-0.94%
iShares Biotechnology ETFIBB2.19M0.02%10.4B USD0.44%$197.55-2.85%
Vanguard Russell 2000 ETFVTWO2.01M0.01%18B USD0.06%$111.05-1.03%
iShares Russell 2000 Growth ETFIWO1.54M0.01%14.25B USD0.24%$350.6-1.34%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFFidelity Enhanced Small Cap ETFFESMiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOiShares Russell 2000 Growth ETFIWOAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
